Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsGLP-1 drugs like Ozempic are well-known for improving blood sugar, weight, and heart health — but a new study finds they may not deliver the same wins for mental health, employment, or relationships. Researchers followed diabetic adults over a decade and found little measurable change in broader life outcomes after starting GLP-1 therapy. The physical benefits remain solid; the broader life-changing effects, less clear.
GLP-1 medications like Ozempic have earned their reputation as game-changers for Type 2 diabetes — improving blood sugar control, reducing cardiovascular risk, and driving significant weight loss. But a new working paper from University of Chicago economists Robert Kaestner and Cuiping Schiman asks a bigger question: do those physical gains ripple out into better mental health, stronger relationships, or improved employment prospects?
The short answer: not really. Analyzing over a decade of data from the nationally representative Medical Expenditure Panel Survey (2012–2023), the researchers tracked the same diabetic adults before and after starting GLP-1 therapy. While GLP-1 users initially appeared to differ from non-users in areas like employment and marital status, those gaps largely vanished when controlling for individual-level changes over time — suggesting the differences reflected who was using the drugs, not what the drugs were doing.
Key Takeaways:
Why it matters: As insurers and government programs debate expanding GLP-1 coverage, this research tempers expectations that these drugs will also deliver broad social or economic benefits. For clinicians and policymakers alike, the message is clear: the physical case for GLP-1s is strong, but broader life transformation effects may be subtler than popularly assumed.
